Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ferrexpo Q2 output slumps as Ukraine govt suspends VAT refunds

(Sharecast News) - Ukraine-focused iron ore pellet maker Ferrexpo reported a slump in second-quarter production as a government suspension of VAT refunds hit liquidity, forcing it to scale back operations. Production fell 40% quarter on quarter to 1.267m tonnes. The lack of liquidity meant Ferrexpo had to downscale operations from two to one pelletising line and also to reduce the production of high-grade concentrate.

"The strong momentum at the start of the year, including our best quarterly production since the full-scale invasion in February 2022, was significantly curtailed in the second quarter as we started to experience the full impact of the Ukrainian tax authorities' decisions to suspend the refund of VAT to our Ukrainian subsidiaries," said interim executive chair Lucio Genovese.

"Lower iron ore prices and lower production, have ... weighed on margins. This has been exacerbated by higher prices for raw materials such as gas and electricity. Throughout the second quarter the Group worked extensively to lower its cost base to remain financially viable."

"This includes placing approximately 37% of employees on reduced working time or on furlough, cuts in procurement of goods and services and a suspension of all non-essential CapEx, CSR and humanitarian spending."

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.